Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women greater than or equal to 18 years
At least one measurable lesion in accordance with RECIST 1.1
Must have an ECOG performance status of 0 or 1.
Patients with advanced solid tumors who have failed after adequate standard treatment, are intolerant to standard treatment, or have no standard treatment available.
Documentation of the presence of a KRAS G12C mutation
Estimated life expectancy ≥12 weeks.
Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose.Men also consent to use adequate contraceptive method within the same time limit.
The subjects are able to comply with the process of the protocol.
You may not be if
Treatment with any of the following: Previous or current treatment with other KRAS G12C inhibitors.
Active brain metastases.
Patients with uncontrolled pleural, ascites or pericardial effusion
Spinal cord compression
Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
Subjects with tumors known to harbor molecular alterations for which targeted therapy is locally approved, except for KRAS G12C.
History of other primary malignancies.
Inadequate bone marrow reserve or organ functions.
Abnormal cardiac examination results.
Severe, uncontrolled or active cardiovascular disorders.
Diabetes ketoacidosis or hyperglycemia hyperosmolality
Uncontrolled hypertension.
Severe bleeding symptoms or bleeding tendencies.
Severe arteriovenous thrombosis occurred
Serious infection.
Continuous use of glucocorticoids
Active infectious diseases.
Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications
Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child Pugh B-grade cirrhosis.
Interstitial lung disease (ILD).
Serious neurological or mental disorders.
Active autoimmune diseases
Clareo Health | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
